Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment.
James P FranciosiEdward B MougeyAndre WilliamsRoberto A Gomez SuarezCameron ThomasChrista L CreechKatherine GeorgeDiana CoraoJohn J LimaPublished in: European journal of pediatrics (2017)
Among children with medically refractory GERD despite PPI therapy, carriage of CYP2C19*17 allele corresponding to the EM phenotype was associated with ARS. Prospective comparative personalized medicine effectiveness studies are needed to determine if CYP2C19 genotype-guided dosing improves response to PPI therapy without a corresponding increase in adverse effects in children. What is known: • Anti-reflux surgery (ARS) is one of the most common surgical procedures performed in children for the indication of refractory gastroesophageal reflux disease (GERD). What is new: • Individualizing PPI medication dosing based on CYP2C19 diplotype may avoid GERD treatment failures and reduce the need for anti-reflux surgery (ARS).
Keyphrases
- gastroesophageal reflux disease
- minimally invasive
- coronary artery bypass
- young adults
- randomized controlled trial
- healthcare
- protein protein
- systematic review
- mesenchymal stem cells
- combination therapy
- percutaneous coronary intervention
- adverse drug
- small molecule
- coronary artery disease
- bone marrow
- acute coronary syndrome